Adrogolide HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524135

CAS#: 166591-11-3 (HCl)

Description: Adrogolide Hydrochloride acts as a selective dopamine receptor D1 agonist. It was developed as a possible treatment for Parkinson's disease, as well as for other applications such as treatment of cocaine addiction. It has mainly been used as its diacetate ester prodrug adrogolide.


Chemical Structure

img
Adrogolide HCl
CAS# 166591-11-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 524135
Name: Adrogolide HCl
CAS#: 166591-11-3 (HCl)
Chemical Formula: C22H26ClNO4S
Exact Mass: 435.13
Molecular Weight: 435.960
Elemental Analysis: C, 60.61; H, 6.01; Cl, 8.13; N, 3.21; O, 14.68; S, 7.35

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 171752-56-0 (free base)   166591-11-3 (HCl)    

Synonym: Adrogolide Hydrochloride; Adrogolide HCl; A-93431.1; A93431.1; A 93431.1; DAS 431; DAS-431; DAS431; ABT 431;ABT-431;ABT431;

IUPAC/Chemical Name: Benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), hydrochloride, (5aR-trans)-

InChi Key: NPEZSCRKHFTLPE-MYXGOWFTSA-N

InChi Code: InChI=1S/C22H25NO4S.ClH/c1-4-5-15-9-17-21(28-15)11-23-18-7-6-14-8-19(26-12(2)24)20(27-13(3)25)10-16(14)22(17)18;/h8-10,18,22-23H,4-7,11H2,1-3H3;1H/t18-,22+;/m1./s1

SMILES Code: CCCC(S1)=CC2=C1CN[C@]3([H])CCC4=CC(OC(C)=O)=C(OC(C)=O)C=C4[C@@]23[H].[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 171752-56-0 (Adrogolide free base) 166591-11-3 (Adrogolide hydrochloride)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 435.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gleason SD, Witkin JM. Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393. Behav Pharmacol. 2004 Feb;15(1):85-9. PubMed PMID: 15075630.

2: Castner SA, Goldman-Rakic PS. Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci. 2004 Feb 11;24(6):1446-50. PubMed PMID: 14960617.

3: Okumu FW, Lee RY, Blanchard JD, Queirolo A, Woods CM, Lloyd PM, Okikawa J, Gonda I, Farr SJ, Rubsamen R, Adjei AL, Bertz RJ. Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. Pharm Res. 2002 Jul;19(7):1009-12. PubMed PMID: 12180532.

4: Giardina WJ, Williams M. Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16. Review. PubMed PMID: 11607045.

5: Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, Thalamas C, Giardina WW, Wright S. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol. 2001 Feb;58(2):249-54. PubMed PMID: 11176963.

6: Self DW, Karanian DA, Spencer JJ. Effects of the novel D1 dopamine receptor agonist ABT-431 on cocaine self-administration and reinstatement. Ann N Y Acad Sci. 2000;909:133-44. PubMed PMID: 10911927.

7: Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 2000 Mar 17;287(5460):2020-2. PubMed PMID: 10720329.

8: Zheng Y, Marsh KC, Bertz RJ, El-Shourbagy T, Adjei AL. Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. Int J Pharm. 1999 Nov 30;191(2):131-40. PubMed PMID: 10564839.

9: Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, Wright S, Carter JH, Nutt JG. ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol. 1999 Jun;45(6):736-41. PubMed PMID: 10360765.

10: Haney M, Collins ED, Ward AS, Foltin RW, Fischman MW. Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology (Berl). 1999 Mar;143(1):102-10. PubMed PMID: 10227086.

11: Shiosaki K, Asin KE, Britton DR, Giardina WJ, Bednarz L, Mahan L, Mikusa J, Nikkel A, Wismer C. Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431. Eur J Pharmacol. 1996 Dec 19;317(2-3):183-90. PubMed PMID: 8997599.

12: Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. J Pharmacol Exp Ther. 1996 Jan;276(1):150-60. PubMed PMID: 8558425.

13: Michaelides MR, Hong Y, DiDomenico S Jr, Asin KE, Britton DR, Lin CW, Williams M, Shiosaki K. (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431). J Med Chem. 1995 Sep 1;38(18):3445-7. PubMed PMID: 7658429.